Key points are not available for this paper at this time.
T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. (Funded by F. Hoffmann-La Roche/Genentech; EMILIA ClinicalTrials.gov number, NCT00829166.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Verma et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d7bd926c394ad7d0bed8c4 — DOI: https://doi.org/10.1056/nejmoa1209124
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Sunil Verma
David Miles
Luca Gianni
New England Journal of Medicine
Massachusetts General Hospital
Dana-Farber Cancer Institute
Duke Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...